Revista medica del Instituto Mexicano del Seguro Social · 2025
[Hidradenitis suppurativa, report with dual therapy: small molecules and biological therapy].
Клинический случайАннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Elizalde-Hernández Paola Denise, Solis-González Andres Jhojairo, Méndez-Flores Fabiola Leonor, Estrada-Aguilar Lorena
Аннотация
BACKGROUND: Hidradenitis suppurativa is an immune-mediated disease characterized by abscesses, deep nodules and fistulas that connect them to each other or connect to the surface, creating infectious processes that are difficult to control, healing of fistulas, retractable tracts and painful ulcers of slow evolution that lead the patient to depression and anxiety. Treatment still shows unsatisfactory results for patient health.
CLINIC CASE: A 27-year-old woman with a 5-year history of this pathology in Hurley stage III is presented. Because of failure to treatment with first lines of management. Anti IL-17 biologic was started, with poor response, so JAK inhibitor was added with adequate response at 4 weeks in the modified Hurley scale, VAS of pain and DLQI.
CONCLUSION: Combined therapy mediated by cytokines and cells of the humoral response of retractile and fistulous lesions in Hurley stages II and III is proposed as an adjuvant in the chronic response of the disease.
CLINIC CASE: A 27-year-old woman with a 5-year history of this pathology in Hurley stage III is presented. Because of failure to treatment with first lines of management. Anti IL-17 biologic was started, with poor response, so JAK inhibitor was added with adequate response at 4 weeks in the modified Hurley scale, VAS of pain and DLQI.
CONCLUSION: Combined therapy mediated by cytokines and cells of the humoral response of retractile and fistulous lesions in Hurley stages II and III is proposed as an adjuvant in the chronic response of the disease.